Pfizer Puts Kosmos AI into Oncology, Immunology, and Internal Medicine Workflows

Pfizer’s Kosmos AI rollout shows how R&D AI is moving from integrated tools to governed, end-to-end workflow execution.

Updated

What is this trend?

Pfizer is embedding Kosmos AI into oncology, immunology, and internal medicine workflows to move R&D from tool adoption to AI-mediated execution across discovery, development, and filing.

  • Pfizer is using Kosmos AI across multiple therapeutic areas, not just as a point solution.
  • The shift is from platform integration to governed execution inside core R&D workflows.
  • Public literature plus proprietary data can now support target ID through regulatory drafting.
  • Validation, provenance, and exception handling are becoming the real differentiators.
  • AI is moving deeper into the execution stack for scientists and R&D managers.

What’s the latest?

Pfizer’s October 29, 2026 deployment of Kosmos AI with Edison Scientific across oncology, immunology, and internal medicine marks the next step in the shift from platform integration to AI-mediated execution.

How it developed

  1. Closed-Loop R&D Platforms, Regulated Infrastructure, and Machine-Readable Experiment Control

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by seniority.

Related trends

Stay ahead in Research & Development (R&D)

Get the weekly Research & Development (R&D) brief in your inbox — the developments, what they mean by seniority, and what to do next.